Avaliação do potencial terapêutico de formulações otológicas com extratos vegetais no tratamento da otite externa canina

Abstract

Otitis externa can be characterized as an inflammation of the external canal, which presents a multifactorial cause, developing clinical signs such as otalgia, otorrhea, erythema and pruritus. In order to use less harnful treatments and avoid the use of antimicrobials, the therapy with plant extract is an option for scarchine new active principles.Thus, the therapeutic potential of two otological pharmaceutical forms with plant extracts was objectified. For the formulation of LCFO 1001 were used extracts of urucum plants (Triticum aestivum), already existing for the compound LCFO 1002, the ethanoic extracts were used from the seeds of the same plants, also a commercial ceruminolic product base Salicylic Acid and Acid For the Control Group. Were avaluated 44 dogs (with LCO-1001, LCFO 1002) group, all groups were at one over 10 days, being evaluated for five years. Moments (D0, D3, D5, D7 and D10), duration of a classic cycle of otalgia, pruritus, otopodal reflex, erythema, amount of cerumen and auditory gauged, post-collected for bacterial culture, fungal cytology. After the evaluation, each clinical sign received a score of 0 to 3, which 0 was considered absent and 3 the most severe form of appearance, from this score a sum was generated per animal and per group during each evaluation day. The results were analyzed statistically through ANOVA, Kruskal-wallis, Friedman, tukey test and McNerman's test. After the 10 days of treatment, there was a reduction of the isolated microorganisms and the clinical sum of all groups, no statistical difference was found between the test and control groups, demonstrating that the compounds LCF0 1001 and LCF0 1002 obtained similar efficiency to a commercial ceruminolytic widely used. These results confirm that the compounds have action in reducing the clinical signs of external canine otitis, as well as they have action in the microbial reduction.